● Recruiting

Asciminib RMP Study

Condition: Chronic Myeloid Leukemia · Sponsor: Novartis Pharmaceuticals

PhaseN/A

Planned participants600

Who can joinAll sexes, 18 Years to 100 Years

Healthy volunteersNo

About this study

This study is a prospective, open-label, multi-center, non-comparative, observational study to assess safety and effectiveness of Asciminib in the real-world clinical setting in Korean Chronic myeloid leukemia (CML) patients.

This description comes directly from the study's public registry record.

Talk to the study team

Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com

Novartis Pharmaceuticals

Always discuss trial participation with your own doctor first.

Locations (17)

Novartis Investigative Site	Wŏnju, Gangwon-do, South Korea	Recruiting
Novartis Investigative Site	Anyang-si, Gyeonggi-do, South Korea	Recruiting
Novartis Investigative Site	Bucheon-si, Gyeonggi-do, South Korea	Recruiting
Novartis Investigative Site	Uijeongbu-si, Gyeonggi-do, South Korea	Recruiting
Novartis Investigative Site	Gyeonggi-do, Korea, South Korea	Recruiting
Novartis Investigative Site	Incheon, Korea, South Korea	Recruiting
Novartis Investigative Site	Seoul, Korea, South Korea	Recruiting
Novartis Investigative Site	Seoul, Seoul, South Korea	Recruiting
Novartis Investigative Site	Seoul, Seoul, South Korea	Recruiting
Novartis Investigative Site	Seoul, Yangcheon gu, South Korea	Recruiting
Novartis Investigative Site	Suwon, Yeongtong Gu, South Korea	Recruiting
Novartis Investigative Site	Jeollanam, South Korea	Recruiting

+ 5 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05943522